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As the use of device therapy broadens, we continue to see
new clinical trials and studies intended to identify the
patients who will benefit most from an implantable
cardioverter-defibrillator (ICD) or cardiac resynchroniza-
tion therapy with defibrillator (CRT-D). Two papers in the
current issue of the Journal (1,2) deal with device therapy for
patients with heart failure. Each study was an effort to more
specifically identify a patient’s needs according to sex, risk of
sudden death, and in consideration of ischemic or nonisch-
emic cardiomyopathy.
See pages 813 and 821
Arshad et al. (1) discuss a clinical trial that addressed sex
differences in the use of either CRT-D or ICD to reduce
death or heart failure. The authors report that in the 1,820
patients enrolled in the MADIT-CRT trial (453 women
and 1,367 men), women had a better result from cardiac
resynchronization therapy combined with a defibrillator
(CRT-D), showing a significant 69% reduction in death or
heart failure and a 70% reduction in heart failure alone
compared with men who had CRT-D. Echocardiographic
variables of left ventricular end-systolic volume (LVESV),
left ventricular end-diastolic volume (LVEDV), and left
ventricular ejection fraction (LVEF) improved to a greater
degree with CRT-D therapy than with ICD therapy in both
the female and male groups. Female patients had consis-
tently greater improvements with CRT-D therapy than did
male patients, with the most significant differences evident
for the group as a whole and in those women with QRS
150 ms or left bundle branch block (LBBB). Women had
82% and 78% reductions in mortality among those with
QRS 150 ms or with LBBB, respectively. The authors
suggest that the differences seen between men and women
in response to CRT-D may be related to greater reverse
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The study by Arshad et al. (1) is interesting, and its most
important results include the clear findings that women
with nonischemic cardiomyopathy and those with either
prolonged QRS duration (QRS 150 ms) or with LBBB
benefit from CRT-D. However, as one analyzes data related
to clinical comparisons between men and women in this
study, several concerns emerge. First, there were twice as
many women with nonischemic cardiomyopathy as men
and 2 to 3 times more men with ischemic heart disease than
women (Table 1). Table 2 suggests that in women with
nonischemic cardiomyopathies and women with LBBB or
QRS 150 ms, CRT-D was superior in reducing the
incidence of death or heart failure or heart failure alone. In
women with ischemic heart disease, CRT-D did not reduce
the incidence of death or heart failure when compared with
men (Table 2). Moreover, Table 3 shows that, while there
are some significant differences between women and men,
such as the comparisons in hemodynamic variables with
regard to reverse remodeling, the absolute differences in
LVESV, LVEDV, and LVEF are very small. They are
slightly larger for women with LBBB or QRS durations
150 ms than for men, but they are still quite small. I
believe one can conclude from the study that women and
men with LVEF 30%, QRS duration 130 ms and class
I or class II symptoms benefit from CRT-D, and that is
especially so for women with nonischemic cardiomyopathies
and LBBB or QRS durations 150 ms. The clinical
imbalance between the frequency of nonischemic versus
ischemic cardiomyopathies between the 2 groups diminish
our confidence in the concept that women benefit more
than men. It is also difficult for one to feel very confident
that the small differences in hemodynamic variables between
men’s and women’s responses to CRT-D provide a com-
plete explanation of the benefits found in selected women.
The Iles et al. (2) study was designed to evaluate the use
of late gadolinium enhancement (LGE) on cardiac mag-
netic resonance imaging (CMRI) in patients with advanced
cardiomyopathy who also had myocardial fibrosis and were
at risk of sudden death. The investigators showed that in
103 patients with advanced cardiomyopathies who met the
criteria for an ICD for primary prevention of sudden cardiac
death (SCD), CMRI with LGE to identify regional fibrosis
helped to identify patients with a high likelihood of appro-
priate ICD discharges. With a median follow-up of 573
days, LGE identified regional fibrosis in 31 of 61 patients
with nonischemic cardiomyopathy and in all 42 patients
with ischemic cardiomyopathy. There was a 29% discharge
rate in the nonischemic cardiomyopathy patients with LGE
compared with a 42% discharge rate in the ischemic
cardiomyopathy group. There were no ICD discharges in
the nonischemic group without LGE, which was signifi-
cantly lower than the rate observed in the ischemic cardio-
myopathy group and in the nonischemic cardiomyopathy
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with and without device therapy and in patients with and
without LGE. The authors conclude that patients with
advanced cardiomyopathies and myocardial fibrosis demon-
strated by LGE have an increased likelihood of appropriate
ICD therapy.
While the investigators’ conclusion is appropriate, the
number of patients studied in each category is relatively
small, and this study needs to be repeated by others with a
larger sample size. In future studies, it would be important
to quantify the volume of fibrosis in patients with and
without appropriate ICD discharges. Clearly, there were
patients with fibrosis in both groups who did not suffer an
ICD discharge. It would also be helpful to compare the
degree of hypertrophy and frequency of nonsustained ven-
tricular tachycardia with the predictive ability of fibrosis
detection by LGE, and to determine whether there is
additive predictive power in combining the 3 methods.
Comparisons with estimates of the “gray zone” (3) as
defined by MRI by the Johns Hopkins School of Medicine
group should also be informative.
In conclusion, as invasive therapies to assure the genera-
tion of electric myocardial activity (pacemakers), prevent
sudden cardiac death (automatic ICDs), and improve thesynchrony of cardiac contraction (CRT) evolve and become
more efficacious and expensive, the need to identify the
patients who benefit the most versus patients likely to be
exposed to invasive procedures without clear-cut benefits
also grows. The 2 papers discussed here represent important
steps in this direction.
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